Biocompatibility and Antimicrobial Studies of Pharmaceutical Formulations

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 590

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary
Interests: assessment of biocompatibility; drug delivery system formulation; application of macromolecules; characterization of dosage forms; in vitro dissolution studies; SEDDS
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary
Interests: cytotoxicity; cell viability; pharmaceutical technology; preservatives; galleria mellonella; pharmaceutical formulation; antimicrobials; biocompatibility; pharmaceutics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
Interests: topical drug delivery; self-emulsifying drug delivery systems; nanocarriers; surfactants; in vitro and in vivo studies; pharmaceutical technology; drug release; skin permeation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

A necessary step in pharmaceutical research is the investigation into the biocompatibility of the new formulation in order to ensure its tolerability. In vitro cell cultures and ex vivo and in vivo animal model systems provide different levels of valuable information about the safety of the developed drug delivery system, and it is essential that one must be aware of the advantages and limitations of each available technique, thus only in considering these factors can the correct conclusion be made while evaluating the results of the formulation. Biocompatibility studies are highly important in the case of antimicrobial formulations, being the most common mechanism of action affecting non-microbial cells, and as such, while the given drug or drugs are effectively inhibiting or terminating the targeted microorganisms, considerable damage impacts the host organism as well.  

The Special Issue cordially welcomes all manuscripts in which the biocompatibility of small molecules, herbal extracts, polymers, or complete drug delivery systems are evaluated, and the antimicrobial effect is tested also. Research articles or reviews in which the comparison of different methods, the relationship of biocompatibility, and the antimicrobial effects are discussed are also covered by the Special Issue.

Prof. Dr. Ildikó Bácskay
Dr. Dániel Nemes
Dr. Liza Józsa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobials
  • biocompatibility
  • in vivo toxicity
  • cytotoxicity
  • antifungals
  • antibacterial
  • antibiotics
  • drug delivery systems
  • in vitro and in vivo models
  • new biologically active agents

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 3852 KiB  
Article
Antitubercular Activity of 7-Methyljuglone-Loaded Poly-(Lactide Co-Glycolide) Nanoparticles
by Bianca Diedericks, Anna-Mari Kok, Vusani Mandiwana, Bhavna Gowan Gordhan, Bavesh Davandra Kana, Suprakas Sinha Ray and Namrita Lall
Pharmaceutics 2024, 16(11), 1477; https://doi.org/10.3390/pharmaceutics16111477 - 20 Nov 2024
Viewed by 362
Abstract
Background/Objectives: Loading of natural products into poly-(lactide-co-glycolic) acid (PLGA) nanoparticles as drug delivery systems for the treatment of diseases, such as tuberculosis (TB), has been widely explored. The current study investigated the use of PLGA nanoparticles with 7-methyljuglone (7-MJ), an active pure compound, [...] Read more.
Background/Objectives: Loading of natural products into poly-(lactide-co-glycolic) acid (PLGA) nanoparticles as drug delivery systems for the treatment of diseases, such as tuberculosis (TB), has been widely explored. The current study investigated the use of PLGA nanoparticles with 7-methyljuglone (7-MJ), an active pure compound, isolated from the roots of Euclea natalensis A. DC. Methods: 7-MJ as well as its respective PLGA nanoparticles were tested for their antimycobacterial activity against Mycobacterium smegmatis (M. smegmatis), drug-susceptible Mycobacterium tuberculosis (M. tuberculosis) (H37Rv), and multi-drug-resistant M. tuberculosis (MDR11). The cytotoxicity of 7-MJ as well as its respective PLGA nanoparticles were tested for their cytotoxic effect against differentiated human histiocytic lymphoma (U937) cells. Engulfment studies were also conducted to determine whether the PLGA nanoparticles are taken up by differentiated U937 cells. Results: 7-MJ has been shown to have a minimum inhibitory concentration (MIC) value of 1.6 µg/mL against M. smegmatis and multi-drug-resistant M. tuberculosis and 0.4 µg/mL against drug-susceptible M. tuberculosis. Whilst promising, 7-MJ was associated with cytotoxicity, with a fifty percent inhibition concentration (IC50) of 3.25 µg/mL on differentiated U937 cells. In order to lower the cytotoxic potential, 7-MJ was loaded into PLGA nanoparticles. The 7-MJ PLGA nanoparticles showed an 80-fold decrease in cytotoxic activity compared to free 7-MJ, and the loaded nanoparticles were successfully taken up by differentiated macrophage-like U937 cells. Conclusions: The results of this study suggested the possibility of improved delivery during TB therapy via the use of PLGA nanoparticles. Full article
Show Figures

Figure 1

Back to TopTop